Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

SpringWorks gets fast track re neurofibromatosis

SpringWorks Therapeutics reports that the FDA has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment...

| By Bill Kelly

Connecticut companies exhibit at BIO convention

Four New Haven-area companies exhibiting at Bio 2019, one the world’s largest forums for the biotech sector. More than 16,000 attendees are taking part in...

| By Bill Kelly

Intensity presents positive Phase 1/2 results

Intensity Therapeutics reports positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American...

| By Kelley Gipson

Bayer and Arvinas to collaborate

Bayer and Arvinas report an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and...

| By Bill Kelly

Sema4 debuts genetic testing services

Stamford-headquartered Sema4 has introduced a line of genomic testing services and digital tools designed to aid oncologists treating cancer patients from the risk assessment to...

| By Kelley Gipson

Thetis reports data supporting it IBD candidate

Thetis Pharmaceuticals reports preclinical data supporting the potential of its lead candidate, TP-317, in inflammatory bowel disease (IBD). TP-317 is a novel salt of Resolvin...

| By Kelley Gipson

Cybrexa data support its alphalex™ technology

Cybrexa Therapeutics reports preclinical data supporting the potential of its proprietary alphalex™ technology platform. Results from multiple preclinical studies demonstrate that alphalex™ successfully enables the combination...

| By Bill Kelly

BioCT welcomes new member Strategic Spaces

Strategic Spaces is a leader in prefabricated construction for interior spaces and commercial furniture solutions. With a trained team of interior designers and construction project...

| By Kelley Gipson

Gene therapy for liver disorder at UConn Health

The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction...